Legal & General Group Plc Boosts Biogen Stake by 10%

Institutional investor now owns over 1.5 million shares of the biotech company.

Mar. 13, 2026 at 9:55am

Got story updates? Submit your updates here. ›

Legal & General Group Plc, a major institutional investor, increased its stake in Biogen Inc. (NASDAQ:BIIB) by 10.1% in the third quarter, according to a recent 13F filing. The firm now owns 1,593,399 shares of the biotechnology company's stock, worth approximately $223 million.

Why it matters

Biogen is a prominent biotech firm focused on developing treatments for neurological and neurodegenerative diseases. Institutional investors closely monitor and adjust their positions in companies like Biogen, as their investment decisions can significantly impact the stock price and market sentiment.

The details

According to the 13F filing, Legal & General Group Plc added 146,583 shares of Biogen to its portfolio during the third quarter. This increase brings the firm's total ownership in Biogen to approximately 1.09% of the company's outstanding shares. The move suggests Legal & General Group Plc's confidence in Biogen's long-term prospects, despite the stock's recent volatility.

  • The 13F filing was submitted on March 13, 2026, covering the third quarter of the previous year.

The players

Legal & General Group Plc

A major institutional investor and one of the largest asset managers in the world, with over $1.3 trillion in assets under management.

Biogen Inc.

A multinational biotechnology company focused on developing treatments for neurological and neurodegenerative diseases, such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

Got photos? Submit your photos here. ›

The takeaway

Legal & General Group Plc's increased stake in Biogen reflects the institutional investor's confidence in the biotech company's long-term potential, despite the stock's recent volatility. This move highlights the importance of monitoring the investment decisions of major institutional players, as they can significantly impact the market's perception and valuation of a company like Biogen.